Fennec Pharmaceuticals
FENC
27 hedge funds and large institutions have $40.7M invested in Fennec Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 9 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
13% more capital invested
Capital invested by funds: $36M → $40.7M (+$4.77M)
2.62% less ownership
Funds ownership: 45.17% → 42.54% (-2.6%)
10% less funds holding
Funds holding: 30 → 27 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Solas Capital Management
Darien,
Connecticut
|
+$411K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$97.3K |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$74.6K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$52.5K |
| 5 |
HFM
Hartford Financial Management
Hartford,
Connecticut
|
+$42.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.18M |
| 2 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$920K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$388K |
| 4 |
Millennium Management
New York
|
-$191K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$51.1K |
FENC Hedge Fund Activity: Q3 2019 in Review
27 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q3 2019, worth a combined $40.7M — up 13% from $36M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of FENC and 6 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Solas Capital Management, adding an estimated $411K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.18M sold.
- 27 institutional investors held Fennec Pharmaceuticals (FENC) as of Q3 2019, down from 30 in Q2 2019.
- Funds reported $40.7M of Fennec Pharmaceuticals stock for Q3 2019, up 13% quarter-over-quarter.
- 6 funds opened new Fennec Pharmaceuticals positions in Q3 2019 and 9 closed out, a net change of -3 holders.
- The largest Fennec Pharmaceuticals buyer in Q3 2019 was Solas Capital Management, an estimated $411K added.
- The largest Fennec Pharmaceuticals seller in Q3 2019 was Opaleye Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q3 2019.